Breaking News

WuXi STA Opens Oligonucleotide and Peptide Manufacturing Facility

Site enhances new modality CRDMO platform capacity for customers.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

WuXi STA, a subsidiary of WuXi AppTec, opened a new large-scale oligonucleotide and peptide manufacturing facility at its Changzhou campus. The new facility underscores WuXi STA’s ongoing commitment to enhance its capacity and capability to meet the fast-growing customer needs for oligonucleotide and peptide therapeutics development and manufacturing worldwide, making more innovative therapies accessible to the patients. With the opening of the new 30,570 square foot oligonucleotide pla...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters